Estrogen-induced cholestasis: Pathogenesis and therapeutic implications

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1289-1296

  Chen, Jiezhong ^a   Zhao, Kong Nan ^b   Liu, Guang Bin ^c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Bile acids; Cholestasis; Estrogen; Multidrug resistance associated transporter

Indexed keywords

17 BETA D GLUCURONIDE; ACTIVATED CARBON; BILE ACID; BILE SALT; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLIC AMP; DEXAMETHASONE; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; RIFAMPICIN; SODIUM ION; TAMOXIFEN; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ABSORPTION; BILE ACID SYNTHESIS; BILE FLOW; BILE SECRETION; BLOOD; CELL PROTECTION; CHEMICAL BINDING; CHOLESTASIS; CYTOTOXICITY; ENTEROHEPATIC CIRCULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN INDUCED CHOLESTASIS; EXCRETION; HEREDITY; INTRAHEPATIC BILE DUCT; LIVER CELL; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILE ACIDS AND SALTS; CHOLESTASIS; ENTEROHEPATIC CIRCULATION; ESTROGENS; HUMANS;

EID: 84885717611     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121061     Document Type: Review

References (94)

1. Chiang, JY: Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 2003; 284: 349-356.
2. Houten, SM, Watanabe M, Auwerx J: Endocrine functions of bile acids. EMBO J 2006; 25: 1419-1425.
3. Rutherford, AE, Pratt DS: Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol 2006; 22: 209-214. (Pubitemid 44090056)
4. Jeffries, GH: Cholestasis of pregnancy. N Engl J Med 1968; 278: 566-567.
5. Lammert, F, Marschall HU, Glantz A, et al.: Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-1021.
6. Holzbach, RT, Sanders JH: Recurrent Intrahepatic Cholestasis of Pregnancy: Observations on Pathogenesis. JAMA 1965; 193: 542-544.
7. Leslie, KK, Reznikov L, Simon FR, et al.: Estrogens in intrahepatic cholestasis of pregnancy. Obstet Gynecol 2000; 95: 372-376. (Pubitemid 30100502)
8. Lammert, F, Marschall HU, Matern S: Intrahepatic Cholestasis of Pregnancy. Curr Treat Options Gastroenterol 2003; 6: 123-132.
9. Metreau, JM, Dhumeaux D, Berthelot P: Oral contraceptives and the liver. Digestion 1972; 7: 318-335.
10. Pauli-Magnus, C, Lang T, Meier Y, et al.: Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102. (Pubitemid 38253644)
11. Vore, M: Estrogen cholestasis. Membranes, metabolites, or receptors? Gastroenterology 1987; 93: 643-649.
12. Chen, J, Raymond K: Nuclear receptors, bile-acid detoxification, and cholestasis. Lancet 2006; 367: 454-456. (Pubitemid 43208887)
13. Russell, DW: The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137-174.
14. Vlahcevic, ZR, Stravitz RT, Heuman DM, et al.: Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 1997; 113: 1949-1957. (Pubitemid 27512154)
15. Chu, XY, Strauss JR, Mariano MA, et al.: Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 2006; 317: 579-589.
16. Konig, J, Rost D, Cui Y, et al.: Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999; 29: 1156-1163. (Pubitemid 29168750)
17. Lee, YM, Cui Y, Konig J, et al.: Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 2004; 14: 213-223. (Pubitemid 38530513)
18. Scheffer, GL, Kool M, de Haas M, et al.: Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002; 82: 193-201. (Pubitemid 34160456)
19. van Aubel, RA, Smeets PH, Peters JG, et al.: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595-603. (Pubitemid 34183923)
20. Keitel, V, Burdelski M, Warskulat U, et al.: Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005; 41: 1160-1172. (Pubitemid 40593925)
21. Marinelli, RA, Lehmann GL, Soria LR, et al.: Hepatocyte aquaporins in bile formation and cholestasis. Front Biosci 2011; 16: 2642-2652.
22. Bouchard, G, Yousef IM, Tuchweber B: Decreased biliary glutathione content is responsible for the decline in bile salt-independent flow induced by ethinyl estradiol in rats. Toxicol Lett 1994; 74: 221-233. (Pubitemid 24380783)
23. Ananthanarayanan, M, Balasubramanian N, Makishima M, et al.: Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 28857-28865.
24. Ridlon, JM, Kang DJ, Hylemon PB: Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-259. (Pubitemid 43276911)
25. Fiorucci, S, Clerici C, Antonelli E, et al.: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313: 604-612. (Pubitemid 40604160)
26. Kato, T, Hayashi H, Sugiyama Y: Short- and medium-chain fatty acids enhance the cell surface expression and transport capacity of the bile salt export pump (BSEP/ABCB11). Biochim Biophys Acta 2010; 1801: 1005-1012.
27. Kipp, H, Arias IM: Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J Biol Chem 2000; 275: 15917-15925. (Pubitemid 30366894)
28. Zhang, Y, Li F, Patterson AD, et al.: Abcb11 Deficiency Induces Cholestasis Coupled to Impaired beta-Fatty Acid Oxidation in Mice. J Biol Chem 2012;
29. McGarr, SE, Ridlon JM, Hylemon PB: Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 2005; 39: 98-109. (Pubitemid 40130020)
30. Schiff, ER, Dietschy JM: Current concepts of bile acid absorption. Am J Clin Nutr 1969; 22: 273-278.
31. Begley, M, Hill C, Gahan CG: Bile salt hydrolase activity in pro biotics. Appl Environ Microbiol 2006; 72: 1729-1738.
32. Wells, JE, Williams KB, Whitehead TR, et al.: Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7alpha-dehydroxylating bacteria in human feces. Clin Chim Acta 2003; 331: 127-134. (Pubitemid 36412034)
33. Schreiber, AJ, Simon FR: Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983; 3: 607-613. (Pubitemid 13078764)
34. Gosland, M, Tsuboi C, Hoffman T, et al.: 17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Research 1993; 53: 5382-5385. (Pubitemid 23342154)
35. Mottino, AD, Cao J, Veggi LM, et al.: Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology 2002; 35: 1409-1419. (Pubitemid 34966895)
36. Koopen, NR, Post SM, Wolters H, et al.: Differential effects of 17alpha-ethinylestradiol on the neutral and acidic pathways of bile salt synthesis in the rat. J Lipid Res 1999; 40: 100-108. (Pubitemid 29022591)
37. Bossard, R, Stieger B, O'Neill B, et al.: Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 1993; 91: 2714-2720. (Pubitemid 23182527)
38. Stieger, B, Fattinger K, Madon J, et al.: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118: 422-430. (Pubitemid 30067515)
39. Pauli-Magnus, C, Meier PJ, Stieger B: Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin Liver Dis 2010; 30: 147-159.
40. Huang, L, Smit JW, Meijer DK, et al.: Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology 2000; 32: 66-72. (Pubitemid 30432367)
41. Crocenzi, FA, Mottino AD, Cao J, et al.: Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol 2003; 285: G449-459. (Pubitemid 36875218)
42. Crocenzi, FA, D'Andrea V, Catania VA, et al.: Prevention of Mrp2 activity impairment in ethinylestradiol-induced cholestasis by ursodeoxycholate in the rat. Drug Metab Dispos 2005; 33: 888-891. (Pubitemid 41002767)
43. Paulusma, CC, Kothe MJ, Bakker CT, et al.: Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 2000; 31: 684-693. (Pubitemid 30118637)
44. Trauner, M, Arrese M, Soroka CJ, et al.: The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255-264. (Pubitemid 27281782)
45. Geier, A, Dietrich CG, Gerloff T, et al.: Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim Biophys Acta 2003; 1609: 87-94. (Pubitemid 36044069)
46. Williams, ET, Leyk M, Wrighton SA, et al.: Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther 2004; 311: 728-735. (Pubitemid 39391561)
47. Gorski, JC, Wang Z, Haehner-Daniels BD, et al.: The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther 2000; 68: 412-417.
48. Harris, RZ, Tsunoda SM, Mroczkowski P, et al.: The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996; 59: 429-435. (Pubitemid 26151625)
49. Kuiper, GG, Carlsson B, Grandien K, et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-870. (Pubitemid 27089735)
50. Yamamoto, Y, Moore R, Hess HA, et al.: Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem 2006; 281: 16625-16631.
51. Yin, Y, Li F, Wang D: [Association between estrogen receptor beta gene polymorphisms in Chinese Uygur patients and intra-hepatic cholestasis of pregnancy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29: 319-322.
52. Lai, K, Harnish DC, Evans MJ: Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner. J Biol Chem 2003; 278: 36418-36429. (Pubitemid 37139971)
53. Kerr, TA, Saeki S, Schneider M, et al.: Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell 2002; 2: 713-720. (Pubitemid 34650068)
54. Lan, Y, Liu J, Cheng H, et al.: [Expressions of SHP and CYP7A1 in pregnant rats with intrahepatic cholestasis]. Zhonghua Gan Zang Bing Za Zhi 2008; 16: 453-456.
55. Savander, M, Ropponen A, Avela K, et al.: Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 2003; 52: 1025-1029. (Pubitemid 36765296)
56. Jacquemin, E: Progressive familial intrahepatic cholestasis. Genetic basis and treatment. Clin Liver Dis 2000; 4: 753-763.
57. Chen, F, Ananthanarayanan M, Emre S, et al.: Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004; 126: 756-764. (Pubitemid 38298324)
58. Folmer, DE, van der Mark VA, Ho-Mok KS, et al.: Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology 2009; 50: 1597-1605.
59. Hayashi, H, Takada T, Suzuki H, et al.: Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11. Hepatology 2005; 41: 916-924. (Pubitemid 40462954)
60. Jansen, PL, Strautnieks SS, Jacquemin E, et al.: Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999; 117: 1370-1379.
61. Dzagania, T, Engelmann G, Haussinger D, et al.: The Histidin-loop is essential for transport activity of human MDR3: A novel mutation of MDR3 in a patient with progressive familial intra-hepatic cholestasis type 3. Gene 2012;
62. Jacquemin, E, De Vree JM, Cresteil D, et al.: The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-1458. (Pubitemid 32322319)
63. Carreras, FI, Lehmann GL, Ferri D, et al.: Defective hepatocyte aquaporin-8 expression and reduced canalicular membrane water permeability in estrogen-induced cholestasis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G905-912. (Pubitemid 46440394)
64. Wang, H, Yan Z, Dong M, et al.: Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet 2012; 285: 1535-1540.
65. Zimmer, V, Krawczyk M, Mahler M, et al.: Severe hepatocellular dysfunction in obstetric cholestasis related to combined genetic variation in hepatobiliary transporters. Clin Exp Obstet Gynecol 2012; 39: 32-35.
66. Castano, G, Burgueno A, Fernandez Gianotti T, et al.: The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther 2010; 31: 583-592.
67. Wei, J, Wang H, Yang X, et al.: Altered gene profile of placenta from women with intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet 2010; 281: 801-810.
68. Chen, J, Farrell GC: Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J Gastroenterol Hepatol 1996; 11: 870-877. (Pubitemid 26297943)
69. Chen, J, Robertson G, Field J, et al.: Effects of bile duct ligation on hepatic expression of female-specific CYP2C12 in male and female rats. Hepatology 1998; 28: 624-630. (Pubitemid 28405407)
70. Ferreira, M, Coxito PM, Sardao VA, et al.: Bile acids are toxic for isolated cardiac mitochondria: a possible cause for hepatic-derived cardiomyopathies? Cardiovasc Toxicol 2005; 5: 63-73. (Pubitemid 40655444)
71. Yerushalmi, B, Dahl R, Devereaux MW, et al.: Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001; 33: 616-626. (Pubitemid 32185224)
72. Phillips, JR, Angulo P, Petterson T, et al.: Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 2745-2750.
73. Kondrackiene, J, Beuers U, Kupcinskas L: Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894-901. (Pubitemid 41242682)
74. Takeuchi, A, Sano N, Takikawa H: Inhibition of ileal bile acid absorption by colestimide. J Gastroenterol Hepatol 2003; 18: 548-553. (Pubitemid 36645289)
75. Kaaja, RJ, Kontula KK, Raiha A, et al.: Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand J Gastroenterol 1994; 29: 178-181. (Pubitemid 24057962)
76. Jonker, JW, Liddle C, Downes M: FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 2012; 130: 147-158.
77. Sanchez Pozzi, EJ, Crocenzi FA, Pellegrino JM, et al.: Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis. J Pharmacol Exp Ther 2003; 306: 279-286. (Pubitemid 36734383)
78. Lorente, S, Montoro MA: [Cholestasis of pregnancy]. Gastroenterol Hepatol 2007; 30: 541-547.
79. Glantz, A, Reilly SJ, Benthin L, et al.: Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008; 47: 544-551. (Pubitemid 351280722)
80. Chappell, LC, Gurung V, Seed PT, et al.: Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012; 344: e3799.
81. Zou, SL, Liu J, Lan Y, et al.: [Effects of farnesoid X receptor ligand on the metabolism of bile acids in rats with estrogen-induced intrahepatic cholestasis of pregnancy]. Zhonghua Gan Zang Bing Za Zhi 2008; 16: 383-386.
82. Misawa, T, Hayashi H, Makishima M, et al.: E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: Structural development study and separation from farnesoid X receptor-agonistic activity. Bioorg Med Chem Lett 2012; 22: 3962-3966.
83. Renga, B, Mencarelli A, D'Amore C, et al.: Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One 2012; 7: e30443.
84. Modica, S, Petruzzelli M, Bellafante E, et al.: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355-365 e351-354.
85. Crocenzi, FA, Mottino AD, Roma MG: Regulation of synthesis and trafficking of canalicular transporters and its alteration in acquired hepatocellular cholestasis. Experimental therapeutic strategies for its prevention. Curr Med Chem 2004; 11: 501-524. (Pubitemid 38292383)
86. Crocenzi, FA, Basiglio CL, Perez LM, et al.: Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP. Biochem Pharmacol 2005; 69: 1113-1120. (Pubitemid 40349023)
87. Kipp, H, Pichetshote N, Arias IM: Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem 2001; 276: 7218-7224.
88. Roelofsen, H, Soroka CJ, Keppler D, et al.: Cyclic AMP stimulates sorting of the canalicular organic anion transporter (Mrp2/cMoat) to the apical domain in hepatocyte couplets. J Cell Sci 1998; 111 (Pt 8): 1137-1145. (Pubitemid 28227113)
89. Benedetti, A, Strazzabosco M, Ng OC, et al.: Regulation of activity and apical targeting of the Cl-/HCO3- exchanger in rat hepatocytes. Proc Natl Acad Sci U S A 1994; 91: 792-796.
90. Diac, M, Kenyon A, Nelson-Piercy C, et al.: Dexamethasone in the treatment of obstetric cholestasis: a case series. J Obstet Gynaecol 2006; 26: 110-114. (Pubitemid 43259272)
91. Glantz, A, Marschall HU, Lammert F, et al.: Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42: 1399-1405. (Pubitemid 43260043)
92. Invernizzi, P, Alvaro D, Crosignani A, et al.: Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39: 1175-1176. (Pubitemid 38428959)
93. Mager, DR, McGee PL, Furuya KN, et al.: Prevalence of vitamin K deficiency in children with mild to moderate chronic liver disease. J Pediatr Gastroenterol Nutr 2006; 42: 71-76. (Pubitemid 43061013)
94. Shen, YM, Wu JF, Hsu HY, et al.: A Pilot Study of an Oral Absorbable Fat-Soluble Vitamin Formulation in Pediatric Patients with Cholestasis. J Pediatr Gastroenterol Nutr 2012;